According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:
1. Bristol Myers Squibb Co (NYSE:BMY)
Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 64, which is 21 points higher than the general drug manufacturer industry average of 43. It passed 24 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -20.48% over the past year, underperforming other general drug manufacturer stocks by -46 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $58.15, an upside of 7.24% from Bristol Myers Squibb Co's current stock price of $54.23.
Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 15.38% have issued a Strong Buy rating, 0% have issued a Buy, 76.92% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.
2. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 4.2% over the past year, underperforming other general drug manufacturer stocks by -22 percentage points.
Johnson & Johnson has an average 1 year
price target of $177.86, an upside of 12.43% from Johnson & Johnson's current stock price of $158.19.
Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Johnson & Johnson, 28.57% have issued a Strong Buy rating, 28.57% have issued a Buy, 42.86% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Astrazeneca (NASDAQ:AZN)
Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 57, which is 14 points higher than the general drug manufacturer industry average of 43. It passed 21 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock lose -1.24% over the past year, underperforming other general drug manufacturer stocks by -27 percentage points.
Astrazeneca has an average 1 year
price target of $82.50, an upside of 21.77% from Astrazeneca's current stock price of $67.75.
Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Astrazeneca, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.